



(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/EP2023/073808

(22) International Filing Date:
30 August 2023 (30.08.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
22193672.7 02 September 2022 (02.09.2022) EP

(71) Applicant: **LEIBNIZ-INSTITUT FÜR IMMUNTHERAPIE (LIT)** [DE/DE]; Franz-Josef-Strauß-Allee 11, 93053 Regensburg (DE).

(72) Inventors: **GATTINONI, Luca**; Wöhrdstraße 47, 93059 Regensburg (DE). **SLAVKOVIC-LUKIC, Dragana**; Furtmayrstrasse 30B, 93053 Regensburg (DE). **LACEY, Neal**; 5519 Homeside Avenue Apartment 2, Los Angeles, California CA90016 (US). **Ji, Yun**; 13405 Stonebridge Terrace, Germantown, Maryland MD20874 (US).


(74) Agent: **HUTTER, Bernd**; Gemlindener Weg 21, 82256 Fürstenfeldbruck (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: THERAPEUTIC USE OF THE miR155 SNP rs377265631

FIGURE 5



(57) Abstract: The present invention relates to the therapeutic use of a single nucleotide polymorphism (SNP) of miR155. The SNP has a multifunctional beneficial effect on immune cells, such as T cells and can be recombinantly employed in the treatment of diseases, such as cancer.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE